JP2019531092A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531092A5
JP2019531092A5 JP2019536689A JP2019536689A JP2019531092A5 JP 2019531092 A5 JP2019531092 A5 JP 2019531092A5 JP 2019536689 A JP2019536689 A JP 2019536689A JP 2019536689 A JP2019536689 A JP 2019536689A JP 2019531092 A5 JP2019531092 A5 JP 2019531092A5
Authority
JP
Japan
Prior art keywords
seq
oligoribonucleotide
sequence
molecule
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531092A (ja
JP6919098B2 (ja
Filing date
Publication date
Priority claimed from ES201631216A external-priority patent/ES2659845B1/es
Application filed filed Critical
Publication of JP2019531092A publication Critical patent/JP2019531092A/ja
Publication of JP2019531092A5 publication Critical patent/JP2019531092A5/ja
Application granted granted Critical
Publication of JP6919098B2 publication Critical patent/JP6919098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536689A 2016-09-19 2017-09-19 筋強直性ジストロフィー1型に対するマイクロrnaの変調及びそのためのマイクロrnaのアンタゴニスト Active JP6919098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201631216 2016-09-19
ES201631216A ES2659845B1 (es) 2016-09-19 2016-09-19 Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
PCT/EP2017/073685 WO2018050930A1 (en) 2016-09-19 2017-09-19 Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor

Publications (3)

Publication Number Publication Date
JP2019531092A JP2019531092A (ja) 2019-10-31
JP2019531092A5 true JP2019531092A5 (cg-RX-API-DMAC7.html) 2019-12-12
JP6919098B2 JP6919098B2 (ja) 2021-08-18

Family

ID=59974404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536689A Active JP6919098B2 (ja) 2016-09-19 2017-09-19 筋強直性ジストロフィー1型に対するマイクロrnaの変調及びそのためのマイクロrnaのアンタゴニスト

Country Status (8)

Country Link
US (2) US11202794B2 (cg-RX-API-DMAC7.html)
EP (2) EP3516059A1 (cg-RX-API-DMAC7.html)
JP (1) JP6919098B2 (cg-RX-API-DMAC7.html)
AU (2) AU2017328728B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037288C (cg-RX-API-DMAC7.html)
ES (1) ES2659845B1 (cg-RX-API-DMAC7.html)
IL (1) IL265461B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018050930A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111448308A (zh) 2017-08-03 2020-07-24 沃雅戈治疗公司 递送aav的组合物和方法
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロrnaの非正規標的を抑制するrna干渉誘導核酸およびその用途
US20210340537A1 (en) * 2020-04-15 2021-11-04 Duquesne University Of The Holy Spirit AN RNA G-QUADRUPLEX STRUCTURE IN PRE-miRNA-1229 AS A THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE AND VARIOUS CANCERS
EP4506010A1 (en) 2022-04-06 2025-02-12 Universitat de València Antagonists of human micro rna mir-100, mir-20, mir-222, mir-181 and mir-92 and uses of same
ES2954008A1 (es) * 2022-04-06 2023-11-17 Univ Valencia Antagonistas de los microRNA humanos miR-100, miR-20, miR-222, miR-181, y miR-92 y usos de los mismos
EP4282964A1 (en) * 2022-05-23 2023-11-29 Universitat de Valéncia Oligonucleotides conjugated to oleic acid and uses thereof
ES3014830A1 (es) * 2023-10-20 2025-04-25 Arthex Biotech S L Oligonucleotidos o analogos de los mismos para el tratamiento de la distrofia del endotelio corneal de fuchs
CN117467664B (zh) * 2023-11-07 2024-06-21 江苏省家禽科学研究所 一种靶向鸡mbnl1基因的反义寡核苷酸及其应用
WO2025114442A1 (en) * 2023-11-28 2025-06-05 Arthex Biotech S.L. Oligonucleotides conjugated to oleic acid and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
EP1549352A4 (en) 2002-05-06 2005-07-27 Nucleonics Inc METHOD OF DISTRIBUTING NUCLEIC ACIDS
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
WO2006069584A2 (en) * 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
EP1984499B1 (en) * 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
US20100004320A1 (en) * 2006-04-03 2010-01-07 Santaris Pharma A/S Pharmaceutical Composition
WO2008036406A2 (en) * 2006-09-21 2008-03-27 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
EP2136846A4 (en) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd THERAPEUTIC OBJECTIVES AND MOLECULES
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
EP2298359A1 (en) 2008-06-04 2011-03-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of controlling degranulation of mast cell
EP2297322A1 (en) * 2008-06-04 2011-03-23 The Board of Regents of The University of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
EP2346905A4 (en) * 2008-10-15 2012-03-07 4S3 Bioscience Inc METHODS AND COMPOSITIONS FOR TREATING MYOTONIC DYSTROPHY
US8852940B2 (en) 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
CA2764480A1 (en) 2009-06-05 2010-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules
EP2275545A1 (en) * 2009-07-16 2011-01-19 Julius-Maximilians-Universität Würzburg Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
CN102869386A (zh) 2010-01-20 2013-01-09 得克萨斯系统大学董事会 用于治疗红细胞增多症的antimiR-451
KR101900770B1 (ko) 2010-07-19 2018-09-20 아이오니스 파마수티컬즈, 인코포레이티드 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
US8729046B2 (en) 2011-12-07 2014-05-20 Albert Einstein College Of Medicine Of Yeshiva University MIR27B is a novel target for treatment of liver fibrosis
KR20130083965A (ko) * 2012-01-16 2013-07-24 김승찬 시험관내 배양된 세포주 에 hsa-miR-218 miRNA에 대한 DNA antisense oligomer 처리 및 신호전달체계 변경 방법
GB201202228D0 (en) 2012-02-08 2012-03-28 Queen Mary & Westfield College Reversal of replicative senescence
CA2871073A1 (en) * 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Mirna modulators of thermogenesis
EP3230454A1 (en) 2014-12-09 2017-10-18 Pierfrancesco Tassone Inhibitors of mir-17-92 cluster for anti-tumor activity in multiple myeloma and other malignancies

Similar Documents

Publication Publication Date Title
JP2019531092A5 (cg-RX-API-DMAC7.html)
JP2023123491A5 (cg-RX-API-DMAC7.html)
FI3442602T3 (fi) Mikrodystrofiinin anto adeno-assioituneella virusvektorilla lihasdystrofian hoitamiseksi
JP2017070307A5 (cg-RX-API-DMAC7.html)
NZ701693A (en) Composition and methods for highly efficient gene transfer using aav capsid variants
JP2015518713A5 (cg-RX-API-DMAC7.html)
JP2016538885A5 (cg-RX-API-DMAC7.html)
MX2021010356A (es) SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
JP2016522674A5 (cg-RX-API-DMAC7.html)
JP2021500064A5 (cg-RX-API-DMAC7.html)
WO2013078199A3 (en) Methods for enhanced in vivo delivery of synthetic, modified rnas
JP2018512876A5 (cg-RX-API-DMAC7.html)
JP2018530530A5 (cg-RX-API-DMAC7.html)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
EP3290055A3 (en) Recombinant virus products and methods for inhibition of expression of dux4
FI3155017T3 (fi) Parannettuja peptidilääkkeitä insuliiniresistenssiin
NO20076013L (no) Toksinpeptidterapeutiske midler
JP2017006120A5 (cg-RX-API-DMAC7.html)
EA201990558A2 (ru) ДОСТАВКА НАЦЕЛЕННЫХ НА ЭКЗОН 2 ПОЛИНУКЛЕОТИДНЫХ КОНСТРУКЦИЙ U7snRNA ПРИ ПОМОЩИ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСА
RU2013107129A (ru) Модуляция экспрессии timp1 и timp2
IN2014DN00101A (cg-RX-API-DMAC7.html)
EA201591992A1 (ru) Эффективная доставка больших генов посредством двойных aav векторов
MX2019015143A (es) Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso.
RU2015103901A (ru) Векторные композиции с модифицированным аденоассоциированным вирусом
JP2012519657A5 (cg-RX-API-DMAC7.html)